Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: MannKind Corporation

Market Cap 1.05B 907M 832M 783M 1.46B 99.8B 1.48B 9.89B 3.85B 48.27B 3.93B 3.85B 168B P/E ratio 2026 *
-108x
P/E ratio 2027 * 23.8x
Enterprise value 1.05B 907M 832M 783M 1.46B 99.8B 1.48B 9.89B 3.85B 48.27B 3.93B 3.85B 168B EV / Sales 2026 *
2.27x
EV / Sales 2027 * 2.01x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day-0.29%
1 week-3.97%
Current month-10.08%
1 month-3.69%
3 months+29.89%
6 months-39.79%
Current year-40.21%
1 week 3.3
Extreme 3.3
3.53
1 month 2.93
Extreme 2.93
3.94
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer 59 30/09/2022
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
05-19Other

Director

82,781 0.0268%
05-19Free

Director

82,781 0.0268%
05-19Other

Director

82,781 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%-3.97%-22.60%-17.72% 1.05B
+0.76%+10.81%+49.79%+110.97% 54.81B
-0.58%-3.99%+50.00%+49.74% 42.96B
-2.93%-6.76%-21.19%-21.54% 21.62B
-0.05%-11.19%+27.91%+370.14% 20.41B
-1.45%-14.80%+15.15%-33.24% 16.03B
-0.06%+4.21%+7.66%-39.85% 15.28B
-1.82%+2.90%+20.24%+167.39% 13.01B
+1.41%-4.01%+12.62% - 11.37B
-4.47%-10.18%-31.47%+666.85% 10.95B
Average -0.95%-5.29%+10.81%+139.19% 20.75B
Weighted average by Cap. -0.62%-3.04%+25.96%+120.49%

Financials

2026 *2027 *
Net sales 462M 400M 367M 345M 643M 44.01B 653M 4.36B 1.7B 21.28B 1.73B 1.7B 74.01B 521M 451M 414M 390M 725M 49.65B 737M 4.92B 1.92B 24.01B 1.96B 1.91B 83.5B
Net income -501K -434K -398K -375K -698K -47.78M -709K -4.74M -1.84M -23.11M -1.88M -1.84M -80.36M 56.85M 49.23M 45.17M 42.5M 79.16M 5.42B 80.4M 537M 209M 2.62B 213M 209M 9.11B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
08/06/26 3.390 $ -0.29% 2,349,399
05/06/26 3.400 $ -3.41% 3,245,421
04/06/26 3.520 $ +4.76% 3,519,408
03/06/26 3.360 $ -2.04% 3,494,664
02/06/26 3.430 $ -2.83% 7,025,035
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.390USD
Average target price
7.594USD
Spread / Average Target
+124.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW